Antia Cousillas Castineiras, Elena Gallardo Martin, Ana Fernandez Montes, Marta Carmona Campos, Marta Covela Rua, Mercedes Salgado Fernandez, María Luz Pellon Augusto, Nieves Martínez Lago, Yolanda Vidal Insua, Elena Brozos Vazquez, Juan De La Camara, Ana Alonso Herrero, Jose Carlos Mendez Mendez
{"title":"Dynamic perspective of the neutrophil-to-lymphocyte ratio in metastatic gastric cancer.","authors":"Antia Cousillas Castineiras, Elena Gallardo Martin, Ana Fernandez Montes, Marta Carmona Campos, Marta Covela Rua, Mercedes Salgado Fernandez, María Luz Pellon Augusto, Nieves Martínez Lago, Yolanda Vidal Insua, Elena Brozos Vazquez, Juan De La Camara, Ana Alonso Herrero, Jose Carlos Mendez Mendez","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The neutrophil-to-lymphocyte ratio (NLR) is an accessible marker from a routine blood test. This study explored the prognostic and predictive value of a change in NLR (c-NLR) after chemotherapy, baseline NLR (bNLR) and chemotherapy response, in metastatic gastric cancer (mGC) patients.</p><p><strong>Methods: </strong>A total of 116 mGC patients treated between 2009 to 2019 at seven hospitals from Galician Research Group on Digestive Tumors (GITuD) were reviewed in a multicentre, ambispective and observational study. NLR was calculated and the optimal cut-off was defined as NLR=3.96 based on ROC method. NLR was determined at baseline and after two chemotherapy cycles in first line treatment. Change NLR was calculated as NLR after two chemotherapy cycles minus bNLR. The relation of bNLR and c-NLR to overall survival (OS) was evaluated by Kaplan-Meier method and compared by log-rank test. Dynamic Score (DScore) based on c-NLR and baseline NLR were correlated with OS and radiological response. Univariate, multivariate and chi-square analyses were performed.</p><p><strong>Results: </strong>Median patient age was 68.7 years, and 66% were male. Univariate analysis showed OS correlation for bNLR ≥3.96 (5.97 vs 10.87 months, p=0.001), c-NLR increase (6.63 vs 10.34 months, p=0.021) and DScore (12.74 vs 7.68 vs 2.43 months, p<0.001). High DScore was associated with radiological progression after two cycles (x2=10.26, p=0.006). Multivariate analysis: bNLR ≥3.96 (HR=2.16, p=0.003) and c-NLR increase (HR= 2.36, p=0.003) were prognostic factors of poor OS.</p><p><strong>Conclusion: </strong>High bNLR and increased NLR after chemotherapy were associated with worse outcome. Dynamic measurement of NLR provides information for stratifying patients to guide optimal treatment.</p>","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":" ","pages":"2131-2140"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The neutrophil-to-lymphocyte ratio (NLR) is an accessible marker from a routine blood test. This study explored the prognostic and predictive value of a change in NLR (c-NLR) after chemotherapy, baseline NLR (bNLR) and chemotherapy response, in metastatic gastric cancer (mGC) patients.
Methods: A total of 116 mGC patients treated between 2009 to 2019 at seven hospitals from Galician Research Group on Digestive Tumors (GITuD) were reviewed in a multicentre, ambispective and observational study. NLR was calculated and the optimal cut-off was defined as NLR=3.96 based on ROC method. NLR was determined at baseline and after two chemotherapy cycles in first line treatment. Change NLR was calculated as NLR after two chemotherapy cycles minus bNLR. The relation of bNLR and c-NLR to overall survival (OS) was evaluated by Kaplan-Meier method and compared by log-rank test. Dynamic Score (DScore) based on c-NLR and baseline NLR were correlated with OS and radiological response. Univariate, multivariate and chi-square analyses were performed.
Results: Median patient age was 68.7 years, and 66% were male. Univariate analysis showed OS correlation for bNLR ≥3.96 (5.97 vs 10.87 months, p=0.001), c-NLR increase (6.63 vs 10.34 months, p=0.021) and DScore (12.74 vs 7.68 vs 2.43 months, p<0.001). High DScore was associated with radiological progression after two cycles (x2=10.26, p=0.006). Multivariate analysis: bNLR ≥3.96 (HR=2.16, p=0.003) and c-NLR increase (HR= 2.36, p=0.003) were prognostic factors of poor OS.
Conclusion: High bNLR and increased NLR after chemotherapy were associated with worse outcome. Dynamic measurement of NLR provides information for stratifying patients to guide optimal treatment.
目的:中性粒细胞与淋巴细胞比值(NLR)是常规血液检查中可获得的标志物。本研究探讨了转移性胃癌(mGC)患者化疗后NLR (c-NLR)变化、基线NLR (bNLR)和化疗反应的预后和预测价值。方法:对2009年至2019年在加利西亚消化肿瘤研究小组(GITuD) 7家医院接受治疗的116例mGC患者进行多中心、双视角和观察性研究。计算NLR,根据ROC法确定最佳截止点NLR=3.96。NLR在基线和两个化疗周期的一线治疗后测定。变化NLR计算为两个化疗周期后的NLR减去bNLR。采用Kaplan-Meier法评价bNLR和c-NLR与总生存期(OS)的关系,并采用log-rank检验进行比较。基于c-NLR和基线NLR的动态评分(DScore)与OS和放射反应相关。进行单因素、多因素和卡方分析。结果:患者中位年龄为68.7岁,男性占66%。单因素分析显示,bNLR≥3.96 (5.97 vs 10.87个月,p=0.001)、c-NLR升高(6.63 vs 10.34个月,p=0.021)和DScore (12.74 vs 7.68 vs 2.43个月)与预后相关。结论:化疗后bNLR高和NLR升高与预后较差相关。NLR的动态测量为患者分层提供信息,以指导最佳治疗。
期刊介绍:
JBUON aims at the rapid diffusion of scientific knowledge in Oncology.
Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board.
With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world.
With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers.
JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.